SGLT2 抑制剂在与衰老相关的心血管疾病中的作用：潜在机制的综述。
SGLT2 Inhibitors in Aging-Related Cardiovascular Disease: A Review of Potential Mechanisms.
机构信息
Department of Cardiology, The Affiliated Hospital of Southwest Medical University, Key Laboratory of Medical Electrophysiology, Ministry of Education and Medical Electrophysiological Key Laboratory of Sichuan Province, Institute of Cardiovascular Research, Southwest Medical University, Luzhou, China.
Department of Rheumatology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China.
出版信息
Am J Cardiovasc Drugs. 2023 Nov;23(6):641-662. doi: 10.1007/s40256-023-00602-8. Epub 2023 Aug 24.
Population aging combined with higher susceptibility to cardiovascular diseases in older adults is increasing the incidence of conditions such as atherosclerosis, myocardial infarction, heart failure, myocardial hypertrophy, myocardial fibrosis, arrhythmia, and hypertension. sodium-glucose cotransporter 2 inhibitors (SGLT2i) were originally developed as a novel oral drug for patients with type 2 diabetes mellitus. Unexpectedly, recent studies have shown that, beyond their effect on hyperglycemia, SGLT2i also have a variety of beneficial effects on cardiovascular disease. Experimental models of cardiovascular disease have shown that SGLT2i ameliorate the process of aging-related cardiovascular disease by inhibiting inflammation, reducing oxidative stress, and reversing endothelial dysfunction. In this review, we discuss the role of SGLT2i in aging-related cardiovascular disease and propose the use of SGLT2i to prevent and treat these conditions in older adults.
人口老龄化加上老年人对心血管疾病的易感性增加，导致动脉粥样硬化、心肌梗死、心力衰竭、心肌肥厚、心肌纤维化、心律失常和高血压等疾病的发病率上升。钠-葡萄糖共转运蛋白 2 抑制剂（SGLT2i）最初是作为一种新型口服药物开发用于 2 型糖尿病患者。出乎意料的是，最近的研究表明，除了对高血糖的作用外，SGLT2i 对心血管疾病也有多种有益作用。心血管疾病的实验模型表明，SGLT2i 通过抑制炎症、减轻氧化应激和逆转内皮功能障碍来改善与衰老相关的心血管疾病过程。在这篇综述中，我们讨论了 SGLT2i 在与衰老相关的心血管疾病中的作用，并提出使用 SGLT2i 来预防和治疗老年人的这些疾病。
Zotero 插件